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Abstract The growth and differentiation of megakaryocytes are 
regulated by thrombopoietin (TPO), a recently characterized 
cytokine which exerts its effects via a member of the hematopoi- 
etin receptor superfamily, c-Mpl. Since many cytokines which 
bind hematopoietin receptors activate the STAT family of tran- 
scription factors, we investigated whether STAT proteins were 
activated by TPO. TPO induced the formation of a DNA-bindiog 
complex recognizing a known STAT-binding sequence. STATS 
was a major component of this DNA-hinding complex, and 
STAT5 was tyrosine phosphorylated in response to TPO. Addi- 
tionally, TPO-induced the tyrosine phosphorylation and DNA- 
binding activity of STAT3. Together with the recent demonstra- 
tion of JAK2 activation in response to TPO, the data presented 
here define a rapid signaling pathway likely to be important in 
TPO-indueed gene regulation. 
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of members of a family of latent cytoplasmic transcription 
factors known as STATs (Signal Transducers and Activators 
of Transcription) [10-12]. The first described members of this 
family, STAT1 and STAT2, are mediators of interferon (IFN)- 
induced gene activation [11], STAT3 is activated by interleukin 
(IL) -6 and IFN~ [13,14], STAT4 by IL-12 [15], STAT5 by IL-2, 
prolactin, growth hormone and erythropoietin [16,17], and 
STAT6 by IL-4 [18]. Upon ligand-receptor interaction, STAT 
proteins become tyrosine phosphorylated within the receptor 
complex and then translocate to the nucleus where they regu- 
late gene transcription through the binding of conserved DNA 
sequences within the promoters of cytokine responsive genes 
[11]. Such sequences are typified by the GRR (IFNy-response 
region) derived from the promoter of the FcyRl gene [19]. 
In this study we investigated whether STAT proteins were 
activated by TPO. TPO induced the tyrosine phosphorylation 
and DNA-binding activity of both STAT5 and STAT3, but not 
of other known STAT family members. STAT5 and STAT3 are 
therefore likely to play important roles in the regulation ofgene 
expression by TPO. 
1. Introduction 2. Materials and methods 
Megakaryocytopoiesis and platelet production are regulated 
at many levels by thrombopoietin (TPO) a recently character- 
ized cytokine that both supports the proliferation of megakar- 
yocyte progenitors and induces their differentiation i to large 
polyploid megakaryocytes [1 3]. The receptor for TPO is 
cMpl, a member of the hematopoietin receptor superfamily 
encoded by the normal cellular homologue of the retroviral 
oncogene v-mpl [4-6]. Like many other cytokines, TPO induces 
the rapid tyrosine phosphorylation f a number of intracellular 
proteins [7 9]. However, the cytoplasmic domains of hemato- 
poietin receptors, including c-Mpl, lack intrinsic kinase activity 
[4,7]. Instead, hematopoietin receptors associate with and acti- 
vate members of the Janus (JAK) family of cytoplasmic protein 
tyrosine kinases [10,11]. Indeed, we and others have recently 
demonstrated that TPO stimulates the rapid activation of 
JAK2, implicating JAK2 in the immediate biochemical re- 
sponse to TPO [8,9]. 
Many cytokines that activate JAK kinases induce activation 
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2.1. Cytokines, antibodies and cell culture 
The following recombinant human cytokines were generously pro- 
vided by the indicated sources: TPO (Kirin Brewery Co. Ltd., Tokyo, 
Japan); IFNa (Hoffmann-LaRoche Inc., Nutley, N J); IL-2 (Cetus On- 
cology Corp., Emeryville, CA); granulocyte-macrophage colony stimu- 
lating factor (GM-CSF) and stem cell factor (SCF) (PeproTech Inc., 
Rocky Hill, NJ). Antisera recognizing STAT1 [20], STAT2 [21] and 
STAT5 [16] were kindly provided by Dr. Chris Schindler (Columbia 
University). Antisera against STATI~ [22], and specific C-terminal 
regions of STAT3 and STAT5 were generously provided by Dr. An- 
drew C. Larner (CBER, FDA). Monoclonal antibodies against STAT3 
and STAT5 were purchased from Transduction Laboratories Inc. (Lex- 
ington, KY). Monoclonal antiphosphotyrosine a tibody, 4G10, was 
purchased from Upstate Biotechnology Inc. (Lake Placid, NY). The 
human megakaryoblastic leukemia cell line Mo7e [23], generously pro- 
vided by Genetics Institute (Cambridge, MA), was maintained as de- 
scribed [9] and cultured in the absence of growth factors for 18-40 h 
before any experiment. 
2.2. Electrophoretic mobility shift assay (EMSA) 
Whole cell extracts were prepared from cytokine stimulated cells as 
previously described [24]. EMSAs were performed as previously de- 
scribed [15,25] using a 32p-end-labeled double-stranded oligonucleotide 
( 5'-AGCATGTTTCAAGGATTTGAGATGTATTTCCCAGAAAA- 
G-Y) corresponding to the GRR of the human FcyRI gene [19]. Oligo- 
nucleotide competition was performed by incubating 100- fold excesses 
of unlabeled GRR or the IFN~-stimulated response lement (ISRE) of 
I SG 15 [26] with cell extracts for 10 min at 4°C before addition of probe. 
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When used, antibodies were incubated with cell extracts for 1 h at 4°C 
before addition of the probe. 
2.3. Oligonueleotide affinity purification and immunoblotting of STAT 
proteins 
Double-stranded GRR oligonucleotide was synthesized with biotin 
covalently attached to the 5'-end of the sense strand. This biotinylated 
GRR was bound to streptavidin-agarose (Sigma Chemical Co., St. 
Louis, MO) resulting in approximately 1.5 pg of DNA per/A of packed 
agarose. Cytokine stimulated cells were lysed in buffer containing 0.1% 
Triton X-100, and lysates incubated for 2 h at 4°C with GRR-bound 
agarose. The precipitates were then washed, resolved by SDS-PAGE, 
transferred to PVDF membranes (Immobilon, Millipore Corp., 
Bedford, MA) and probed with monoclonal anti-STAT antibodies ac- 
cording to the manufacturer's in tructions. 
2.4. lmmunoprecipitation and antiphosphotyrosine immunoblotting 
Cytokine-stimulated cells were lysed in 1% Triton X-t00 buffer as 
previously described [27], immunoprecipitated with anti-STAT anti- 
sera coupled to protein A-Sepharose and separated by 8% SDS-PAGE. 
Resolved proteins were transferred to Immobilon and immunoblotted 
with anti-phosphotyrosine a tibody, 4G10 as previously described [27]. 
3. Results 
3.1. TPO induces a GRR-binding complex containing tyrosine 
phosphorylated components 
We have previously demonstrated that TPO stimulates pro- 
liferation and ligand-dependent activation of JAK2 in the 
megakaryoblastic cell line Mo7e [9]. We therefore used these 
cells to investigate the activation of STATs by TPO. Cytokine- 
activated STAT proteins bind to a series of palindromic DNA 
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Fig. 1. TPO induces aDNA-binding complex that recognizes the GRR 
of the Fc~'R 1 gene. Mo7e cells were incubated with medium alone, 200 
ng/ml TPO or 20 ng/ml GM-CSF for the indicated times and whole cell 
extracts prepared. 10 pg of each extract was analyzed by EMSA using 
a radiolabeled GRR oligonucleotide probe. Competition was per- 
formed by adding 100-fold molar excess of unlabeled GRR (lanes 5 7) 
or [SRE (lanes 8-10) oligonucleotides to the DNA-binding reaction 
prior to electrophoresis. 
oligonucleotides with the consensus equence TTNCNNNAA 
[11]. Such sequences are typified by the GRR of the Fc~'RI gene 
[19], which has been shown to bind STAT-containing com- 
plexes induced by a number of different cytokines [12]. Since 
no TPO-activated genes have yet been defined, we performed 
EMSAs using a radiolabeled GRR probe to analyze the DNA- 
binding proteins induced by TPO. Extracts from TPO-stimu- 
lated Mo7e cells (Fig. 1, lanes 2 and 3), but not from unstimu- 
lated cells (lane 1) contained a GRR-binding complex 
(indicated by an arrow). A similarly migrating complex was 
also strongly induced by GM-CSF (lane 4). In addition, a 
second, more slowly migrating GRR-binding complex was 
clearly induced by GM-CSF, but only very weakly by TPO. 
This difference may possibly result from differences in signal 
intensity since TPO typically induced weaker GRR-binding 
complexes than did GM-CSF. The binding of these cytokine- 
induced complexes to the GRR probe was inhibited by compe- 
tition with unlabeled GRR oligonucleotide (Fig. 1, lanes 5-7) 
but not by unlabeled ISRE (lanes 8-10), demonstrating their 
sequence specificity. The assembly of STAT-containing DNA- 
binding complexes requires that certain components be tyro- 
sine phosphorylated [12,28]. Accordingly, incubation of ex- 
tracts from TPO-stimulated cells with monoclonal an- 
tiphosphotyrosine antibodies prior to the addition of radiola- 
beled GRR probe markedly inhibited the formation of the 
TPO-induced GRR-binding complex (data not shown), sug- 
gesting that this complex contained proteins phosphorylated on
tyrosine residues, possibly STAT proteins. 
3.2. Tyrosine phosphorylation of STAT proteins in response to 
TPO 
To identify the STAT proteins activated by TPO we per- 
formed immunoprecipitation with specific anti-STAT antisera 
followed by antiphosphotyrosine mmunoblotting. Treatment 
of Mo7e cells with IFN~ induced tyrosine phosphorylation f 
STAT1 (Fig. 2A, lane 4) and STAT2 (Fig. 2B, lane 4) which 
co-immunoprecipitated from IFN~-stimulated cells as previ- 
ously described [11,29]. However, neither TPO nor GM-CSF 
induced tyrosine phosphorylation f STAT1 (Fig. 2A, lanes 2 
and 3) or STAT2 (Fig. 2B, lanes 2 and 3). Equal protein loading 
was confirmed by reblotting each membrane with the im- 
munoprecipitating antibody (data not shown). We also did not 
detect inducible tyrosine phosphorylation of STAT4 in re- 
sponse to TPO (data not shown). 
Therefore, we next examined the phosphorylation f STAT5 
and STAT3 in response to TPO. In agreement with previous 
reports [16,17] STAT5 was inducibly phosphorylated in re- 
sponse to both GM-CSF (Fig. 2C, lane 3) [17] and IL-2 (lane 
4) [16]. Importantly, treatment of the cells with TPO also 
strongly induced the tyrosine phosphorylation f STAT5 (Fig. 
2C, lane 2). Likewise, TPO readily induced tyrosine phospho- 
rylation of STAT3 (Fig. 2D, lane 2). In contrast however, the 
growth-factor GM-CSF (at concentrations that induced readily 
detectable phosphorylation f JAK2; data not shown) induced 
much less tyrosine phosphorylation of STAT3 (Fig. 2D, lane 
3) than did TPO. As expected, STAT3 was also inducibly 
phosphorylated in response to IFN~ (Fig. 2D, lane 4) [14]. 
Again, the presence of equal amounts of STAT5 and STAT3 
in each lane was demonstrated by immunoblotting with mono- 
clonal antibodies (data not shown). Together these data indi- 
cate that STAT5 and STAT3, but not STAT1, STAT2, or 
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Fig. 2. TPO induces tyrosine phosphorylation f STAT5 and STAT3, but not STAT1 or STAT2. Mo7e cells were stimulated for 15 rain as described, 
and lysates then immunoprecipitated with anti-STAT antisera, resolved by SDS-PAGE, and immunoblotted with the antiphosphotyrosine antibody, 
4G10. (A) Anti-STATh lane 1 -- medium alone; lane 2 = TPO (200 ng/ml); lane 3 = GM-CSF (50 ng/ml); lane 4 = IFN~ (1000 U/ml). (B) Anti- 
STAT2: lane 1 = medium alone; lane 2 = TPO; lane 3 = GM-CSF; lane 4=IFN~. (C) Anti-STAT5: lane l=medium alone; lane 2 = TPO; lane 
3 = GM-CSF; lane 4 = IL-2 (1000 U/ml). (D) Anti-STAT3: lane 1 = medium alone; lane 2 = TPO; lane 3 = GM-CSF; lane 4 = IFNa. 
STAT4 are tyrosine phosphorylated following stimulation of 
Mo7e cells with TPO. 
3.3. STAT3 and STAT5 are components of the TPO-#tduced 
DNA-binding complex 
In order to confirm the activation of STAT5 and STAT3 by 
TPO, and to show that these proteins were indeed components 
of the TPO-induced DNA-binding complex, we first used the 
combined techniques of oligonucleotide affinity purification 
and Western blotting. TPO-induced GRR-binding complexes 
were affinity purified by incubation of whole cell extracts with 
GRR-conjugated agarose. GRR-bound proteins were resolved 
by SDS-PAGE and immunoblotted with specific anti-STAT 
antibodies. Whereas GRR precipitates from unstimulated 
Mo7e cells contained neither STAT5 (Fig. 3A, lane 1) nor 
STAT3 (Fig. 3B, lane 1), STAT5 was detected in GRR-precip- 
itates from cells stimulated with TPO (Fig. 3A, lane 2) and 
GM-CSF (Fig. 3A, lane 3). Similarly, STAT3 was present in 
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GRR-precipitates from cells stimulated with TPO (Fig. 3B, lane 
2) and IFN~ (Fig. 3B, lane 4), but not in precipitates from cells 
treated with GM-CSF (Fig. 3B, lane 3). The inability to detect 
GRR-bound STAT3 in response to GM-CSF is consistent with 
the comparatively ow level of STAT3 tyrosine phosphoryla- 
tion induced by this cytokine (Fig. 2D). 
To further analyze the composition of the TPO-induced 
DNA binding complex, we performed EMSAs in which antis- 
era recognizing specific STAT proteins were added to the 
DNA-binding reaction before addition of the 32p-labeled probe. 
Antiserum against STAT1 supershifted the GRR-binding com- 
plex induced by IFN~ (Fig. 3C, lane 6), but not the TPO- 
induced complex (lane 5), confirming that TPO does not acti- 
vate STAT1 in these cells. Similarly, anti-sera gainst STAT2 
and STAT4 also had no effect on the TPO-induced DNA- 
binding complex (data not shown). Addition of anti-STAT3 
antiserum also did not alter the GRR-binding complex induced 
by TPO (data not shown). Importantly however, using Mo7e 
cells, the antiserum also failed to alter the complexes induced 
by a number of other cytokines previously shown to induce 
STAT3 binding to the GRR, including IL-2 and IFNc~ [16,30] 
(data not shown), suggesting that the antiserum was unable to 
supershift any STAT3 containing DNA-bound complex from 
these cells. 
However, in support of the data presented above, addition 
of antiserum recognizing STAT5 produced a distinct super- 
shifted complex in extracts from TPO-treated (Fig. 3C, lane 8), 
but not IFN~-treated (lane 9) cells, indicating the presence of 
STAT5 in the complexes induced by TPO but not by IFN~. 
Control antiserum had no effect on the GRR-binding com- 
plexes induced by either TPO (lane 11) or IFNc~ (lane 12). These 
data clearly confirm that STAT5 and STAT3 are components 
of the TPO-induced DNA binding complex, and suggest an 
important role for these proteins in TPO-induced gene activa- 
tion. 
4. Discussion 
In this report we demonstrate by both oligonucleotide affin- 
ity purification and by EMSA that TPO induces the rapid 
assembly of a DNA-binding complex containing STAT5, which 
is tyrosine phosphorylated in response to TPO. In addition, 
TPO induces the tyrosine phosphorylation a d DNA-binding 
of STAT3. Together with the recent finding that TPO activates 
JAK2 [8,9], these data identify a rapid and direct signaling 
pathway by which TPO-induced gene activation might occur. 
TPO induces both the proliferation of megakaryocyte pro- 
genitor cells and their differentiation i to mature, polyploid 
(.__ 
Fig. 3. The TPO-indueed DNA-binding complex contains STAT5 and 
STAT3. (A and B) Mo7e cells were incubated with medium alone (lanes 
1), TPO (lanes 2), GM-CSF (lanes 3), or IFN~ (Fig. 3B, lane 4) lysed 
and incubated with GRR-coupled agarose. GRR-bound proteins were 
resolved by SDS-PAGE, and immunoblotted with antibody against (A) 
STAT5 or (B) STAT3. (C) Extracts from Mo7e cells treated with 
medium alone (lanes 1, 4, 7, 10), TPO (lanes 2, 5, 8, 11) or IFN~ (lanes 
3, 6, 9, 12) were incubated for 1 h with buffer alone (lanes 1 3), with 
anti-STAT1 antiserum (lanes 3~6), with antiserum recognizing STATS 
(lanes 7 9), or with control antiserum (lanes 10~12). Extracts were then 
incubated with GGR probe and analyzed by EMSA. 
megakaryocytes [1-3,6]. While the genes activated by TPO dur- 
ing these two processes have not been defined, our studies 
suggest hat the activation of STAT5 and STAT3 might be 
important in the induction of megakaryocyte growth and dif- 
ferentiation. STATS is activated by a number of other cytoki- 
nes in addition to TPO, including prolactin, growth hormone, 
GM-CSF, erythropoietin [17], and IL-2 [16], and may therefore 
be a common element in the growth and differentiation signals 
transduced by these cytokines. The identification of STATS 
regulated genes could provide valuable insight into the regula- 
tion of cell proliferation and differentiation. Moreover, disreg- 
ulation of STAT5 activity could play a role in disorders of cell 
growth and maturation such as cancer, suggesting that STAT5 
might be a novel target for pharmacological treatment of such 
diseases. 
We have recently demonstrated that, like TPO, the T cell 
growth factors IL-2, IL-7, IL-9 and IL-15 (cytokines whose 
receptors each utilize the common y chain (),c)) also activate 
STAT5 and STAT3 [16]. This is intriguing since these cytokines 
each activate JAK1 and JAK3 [16], whereas TPO activates 
JAK2 [9], indicating that the ability of a cytokine to activate 
specific STATs cannot be correlated with the activation of a 
given JAK. Instead, recent evidence suggests that the selective 
utilization of STATs by cytokines is determined by specific 
STAT binding motifs within the receptor itself [31]. 
Despite the fact that they all activate STAT5 and STAT3, 
IL-2, IL-7, IL-9 and TPO each trigger a range of different 
biological effects in different cell types suggesting that factors 
other than STATs themselves may important determinants of
cytokine specificity. STATs often bind to DNA as complexes 
with other STATs or with other non-STAT proteins (for exam- 
ple members of the IRF-1 family) [32]. The combinatorial sso- 
ciation of these factors may be one mechanism by which signal 
diversity is achieved. In addition, many other signaling mole- 
cules such as the MAP kinase family are activated by cytokines. 
Such pathways also regulate cytokine-induced gene expression, 
and may even directly modulate STAT activation. By interact- 
ing with other signal transduction pathways to induce expres- 
sion of distinct sets of genes, STAT3 and STAT5 may subserve 
roles in both the growth and differentiation ofmegakaryocytes. 
Elucidation of the exact composition of the STAT complexes for- 
med in response to TPO and identification ofother signaling path- 
ways activated by TPO may lead to a better understanding of the 
molecular mechanisms for the many biological effects of TPO. 
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